What are your top takeaways in Head & Neck Cancers from ASCO 2022?

Topics: Head and Neck Cancers • Radiation Oncology • Medical Oncology • ASCO 2022

What were your “top 3” presentations/studies coming out of the meeting this year and how will it impact your own clinical practice?

Answer from: Radiation Oncologist at Academic Institution

In nasopharyngeal cancer, the group from Sun Yat-Sen University presented the results of a non-inferiority, randomized phase III study comparing RT alone vs RT concurrent with cisplatin for intermediate-risk patients (stage II and T3N0M0) (Ma et al., 2022 ASCO Annual Meeting, abstract #6000). They f...

Comments

Radiation Oncologist at Instituto Nacional del Cancer Chile
Thank you so much for this review.

Answer from: Radiation Oncologist at Community Practice

Tata Memorial Docetaxel Trial (6003) Takeaway: Docetaxel improved DFS and OS compared to RT alone in cisplatin-ineligible patients. Details: 356 cisplatin-ineligible patients with locally advanced disease needing definitive or adjuvant CRT. Randomized to concurrent docetaxel 15 mg/m2 weekly f...

Comments

Radiation Oncologist at University of Michigan
Agree with Dr. @Gary V. Walker regarding the ...

Related Questions